{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matched+control&page=13",
    "query": {
      "intervention": "Matched control",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 6059,
    "total_pages": 606,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matched+control&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matched+control&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T04:21:53.967Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02834793",
      "title": "Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lennox-Gastaut Syndrome (LGS)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2016-12-13",
      "completion_date": "2021-07-19",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 31,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834793"
    },
    {
      "nct_id": "NCT04176133",
      "title": "Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Entolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Influenza vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert J. Pignolo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-10-30",
      "completion_date": "2022-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176133"
    },
    {
      "nct_id": "NCT05252949",
      "title": "OEA for Targeting Lipid Metabolism in GWI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gulf War Illness"
      ],
      "interventions": [
        {
          "name": "Oleoylethanolamide (OEA)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Roskamp Institute Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 52,
      "start_date": "2021-06-10",
      "completion_date": "2025-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 1,
      "location_summary": "Sarasota, Florida",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05252949"
    },
    {
      "nct_id": "NCT01417052",
      "title": "A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "50 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "100 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "150 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "200 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "250 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "300 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "400 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "250 mg LX3305 BID",
          "type": "DRUG"
        },
        {
          "name": "500 mg LX3305 QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2011-09",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-08-02",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01417052"
    },
    {
      "nct_id": "NCT04704843",
      "title": "A Study of Guselkumab in Adult Participants With Celiac Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Celiac Disease"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-17",
      "completion_date": "2021-09-13",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 4,
      "location_summary": "Lancaster, California • Chesterfield, Michigan • Wyoming, Michigan + 1 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Chesterfield",
          "state": "Michigan"
        },
        {
          "city": "Wyoming",
          "state": "Michigan"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704843"
    },
    {
      "nct_id": "NCT02575833",
      "title": "Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Angina"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 89,
      "start_date": "2015-11-23",
      "completion_date": "2017-04-13",
      "has_results": true,
      "last_update_posted_date": "2018-08-24",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 8,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575833"
    },
    {
      "nct_id": "NCT05120349",
      "title": "A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2022-02-21",
      "completion_date": "2032-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 15,
      "location_summary": "Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Grand Junction",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05120349"
    },
    {
      "nct_id": "NCT04701658",
      "title": "A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Bamlanivimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2021-02-01",
      "completion_date": "2021-06-22",
      "has_results": true,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701658"
    },
    {
      "nct_id": "NCT03732638",
      "title": "Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1590,
      "start_date": "2018-11-14",
      "completion_date": "2021-02-02",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 93,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732638"
    },
    {
      "nct_id": "NCT01193478",
      "title": "A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "GS-5885",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 71,
      "start_date": "2010-08",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-21",
      "last_synced_at": "2026-10-20T04:21:53.967Z",
      "location_count": 13,
      "location_summary": "Anaheim, California • Cypress, California • National City, California + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01193478"
    }
  ]
}